McKay, Ailsa J <br/><br/>
Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.  [electronic resource] 

 -  Atherosclerosis  08 2018 
 - 434-443 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-1484 
<br/><br/><label>Standard No.: </label>10.1016/j.atherosclerosis.2018.05.047  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Age Factors<br/>Blood Chemical Analysis--economics<br/>Cholesterol--blood<br/>Clinical Decision-Making<br/>Cost-Benefit Analysis<br/>DNA Mutational Analysis--economics<br/>Decision Support Techniques<br/>Decision Trees<br/>Genetic Markers<br/>Genetic Predisposition to Disease<br/>Health Care Costs<br/>Humans<br/>Hyperlipoproteinemia Type II--blood<br/>Infant<br/>Markov Chains<br/>Mass Screening--economics<br/>Models, Economic<br/>Mutation<br/>Phenotype<br/>Predictive Value of Tests<br/>Prognosis<br/>Quality of Life<br/>Quality-Adjusted Life Years<br/>Time Factors<br/>United Kingdom